Please use this identifier to cite or link to this item: https://doi.org/10.1080/02841860600702076
Title: Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma
Authors: Chuah, B.
Lim, R.
Boyer, M.
Ong, A.-B.
Wong, S.-W.
Kong, H.-L. 
Millward, M.
Clarke, S.
Goh, B.-C.
Issue Date: 2007
Citation: Chuah, B., Lim, R., Boyer, M., Ong, A.-B., Wong, S.-W., Kong, H.-L., Millward, M., Clarke, S., Goh, B.-C. (2007). Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncologica 46 (2) : 234-238. ScholarBank@NUS Repository. https://doi.org/10.1080/02841860600702076
Abstract: Hepatocellular carcinoma (HCC) is a hypervascular tumour, which overexpresses vascular endothelial growth factor. Thalidomide is an antiangiogenic agent with activity in refractory multiple myeloma. The purpose of this multi-centre phase II study was to evaluate the efficacy and toxicity of thalidomide in patients with advanced HCC. From February 2000 to November 2001, 37 patients with histologically proven, bi-dimensionally measurable advanced, unresectable HCC were enrolled. The starting dose of Thalidomide was 100 mg per day and escalated weekly by 100 mg to a maximum dose of 800 mg/day according to individual patient tolerance. Radiological tumour response and treatment related toxicities were prospectively assessed. Thirty-seven patients were evaluable for toxicity and 24 patients were evaluable for response. The median Thalidomide dose was 400 mg/day. There was no complete response (CR). One patient had a radiological partial response (PR) (3%; 95% confidence interval [95% CI], 0% to 8%) and six (16%) patients had stable disease for more than 6 months. Somnolence and fatigue were the most common side effects, occurring in 84% and 73% of patients respectively. Thalidomide monotherapy is tolerable and associated with modest antitumour activity in advanced HCC. © 2007 Taylor & Francis.
Source Title: Acta Oncologica
URI: http://scholarbank.nus.edu.sg/handle/10635/131526
ISSN: 0284186X
DOI: 10.1080/02841860600702076
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

16
checked on Jul 17, 2018

WEB OF SCIENCETM
Citations

16
checked on Jul 9, 2018

Page view(s)

8
checked on Jul 5, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.